Latest Headlines

  1. UCLA Research Improves Molecular Probe For Drug Discovery 4/28/2026

    A UCLA-led international research collaboration unveiled a new technology that may help scientists better understand how small molecules, including many drugs, bind to proteins. The invention works with an existing lab method called photo-crosslinking.

  2. BioDuro And CTI Biotechnology Enter Strategic Partnership To Accelerate Preclinical Drug Development 4/28/2026

    BioDuro, a trusted global Contract Research, Development and Manufacturing Organization (CRDMO), today announced a strategic partnership with CTI Biotechnology (Suzhou) Co., Ltd. ("CTI Biotechnology"), a leading provider of preclinical research services for innovative drug development.

  3. BRC Therapeutics Announces Investigational New Drug Application For BRC-002 Cleared By FDA 4/28/2026

    BRC Therapeutics (BRC), a pharmaceutical company developing therapeutics for neurological and inflammatory diseases, announced today that the company can proceed with a Phase I study to further establish safety of BRC-002 in healthy volunteers.

  4. U.S. Food And Drug Administration Accepts New Drug Application For Zipalertinib For The Treatment Of Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations 4/28/2026

    Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab.

  5. Taking The Guesswork Out Of Drug Development For Chagas Disease 4/24/2026

    Researchers at Kent have established a computational protocol that could accelerate the development of more effective treatments for life-threatening parasitic infections such as Chagas disease, by enabling scientists to accurately identify reactions that can result in successful drug candidates without the need for trial and error.

  6. Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma By The US FDA 4/23/2026

    Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of mesothelioma, which is a rare and difficult to treat cancer.

  7. ImmunoForge To Accelerate CNS Drug Development With Innovative BBB Shuttle Platform 'LMT15' 4/22/2026

    ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company specializing in treatments for rare and muscular diseases, is poised to redefine Central Nervous System (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation Blood-Brain Barrier (BBB) shuttle technology.

  8. Celerion Announces Majority Investment From THL Partners 4/22/2026

    Celerion, a global leader in clinical pharmacology and bioanalytical sciences, today announced a majority investment from THL Partners (“THL”), a premier private equity firm investing in middle market growth companies.

  9. Candidate Breast Cancer Drug Overloads Tumors With 'Surge' Of Toxic Lipids 4/22/2026

    An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice. Triple-negative breast cancer lacks three common drug targets, making it one of the most aggressive forms of the disease.

  10. Pegrizeprument Granted Orphan Drug Designation For Prevention Of Organ Rejection In Heart Transplant Patients 4/22/2026

    Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced today that pegrizeprument (also known as VEL-101), a novel investigational maintenance immunosuppressive agent, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant.